Real-World Studies
MRI Habitat Model Predicts ICI Response and Survival in Hepatocellular Carcinoma
Fu et alLa radiologia medica

Tumor heterogeneity hinders accurate prediction of response to immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC). In a multicenter study including 883 HCC patients from six institutions and public databases, investigators evaluated an MRI habitat model using routine in-phase (IP) and opposed-phase (OP) sequences, which provide complementary structure- and lipid-related information, to predict response to ICI therapy.
Models assessing habitat, radiomics, peritumoral, clinical, and combined features were developed to predict partial response across five institutions. Among independent models, the habitat model showed numerically higher AUCs, with 0.923 in the training set and 0.918 and 0.897 in two external validation sets. The combined model showed favorable performance with AUCs of 0.959, 0.965, and 0.955 in the training and validation cohorts, respectively. Calibration curves showed generally close agreement, while decision curve analyses suggested potential clinical net benefit of the habitat and combined models.
Kaplan–Meier survival analysis showed that patients with higher habitat scores had significantly longer progression-free and overall survival (all P < 0.05). Exploratory biological analyses using Shapley additive explanations (SHAP), multi-omics, and pathology showed that higher habitat scores were associated with enhanced immune activity, downregulated fatty acid-related pathways, and shorter tumor–inflammatory spatial distances, indicating potential for treatment-response prediction and prognostic stratification in HCC.
Key Takeaways
- In external validation cohorts, the MRI habitat model achieved AUCs of 0.918 and 0.897 for predicting partial response to immune checkpoint inhibitors in hepatocellular carcinoma, while the combined model reached AUCs of 0.965 and 0.955.
- Patients with higher MRI habitat scores had significantly longer progression-free and overall survival under immune checkpoint inhibitor therapy (all P < 0.05).
- Higher MRI habitat scores were biologically associated with enhanced immune activity, downregulated fatty acid-related pathways, and shorter tumor–inflammatory spatial distances on exploratory multi-omics and pathological evaluation.
Read the original sourceLa radiologia medica
